Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.73 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.67 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.67 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.67 |
| ▸ | OGG1 | O15527 | 1/20 | 0.65 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 9/20 | 0.58 |
| ▸ | NPC1 | O15118 | 8/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 10/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.55 |
| ▸ | TP53 | P04637 | 3/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7088656 | 0.86 | MCL1 (0.76) | MCL1HDAC1HDAC8HDAC6OGG1 | |
| SCHEMBL29911721 | 0.85 | MCL1 (1.00) | MCL1HDAC1HDAC8HDAC6OGG1 | |
| SCHEMBL444722 | 0.85 | MCL1 (1.00) | MCL1HDAC1HDAC8HDAC6OGG1 | |
| SCHEMBL12644102 | 0.85 | MCL1 (0.73) | MCL1HDAC1HDAC8HDAC6OGG1 | |
| SCHEMBL2610241 | 0.83 | MCL1 (0.71) | MCL1HDAC1HDAC8HDAC6OGG1 | |
| SCHEMBL5418076 | 0.83 | MCL1 (0.71) | MCL1HDAC1HDAC8HDAC6OGG1 | |
| SCHEMBL7675240 | 0.83 | MCL1 (0.71) | MCL1HDAC1HDAC8HDAC6OGG1 | |
| Hydrochloric Acid SCHEMBL4950639 | 0.83 | MCL1 (0.96) | MCL1HDAC1HDAC8HDAC6OGG1 | |
| SCHEMBL27629193 | 0.81 | MCL1 (0.53) | MCL1HDAC1HDAC8HDAC6OGG1 | |
| SCHEMBL11177633 | 0.80 | MCL1 (0.72) | MCL1HDAC1HDAC8HDAC6OGG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0731800-A1 | IMPROVED PROCESS FOR THE SYNTHESIS OF 3-CHLOROBENZO [b]THIOPHENE-2-CARBONYL CHLORIDES | WARNER-LAMBERT COMPANY (US) | 1996-09-18 | — | — | EP | claimed |
| US-5426191-A | Treating substituted cinnamic acids with 4-N,N*-disubstituted aminopyridines, then with thionyl chloride | WARNER-LAMBERT COMPANY (US) | 1995-06-20 | — | — | US | claimed |
| WO-1995015323-A1 | IMPROVED PROCESS FOR THE SYNTHESIS OF 3-CHLOROBENZO[b]THIOPHENE-2-CARBONYL CHLORIDES | WARNER-LAMBERT COMPANY (US) | 1995-06-08 | — | — | WO | claimed |
| US-20260070921-A1 | COMPOUND, ENDOPLASMIC RETICULUM STRESS INHIBITOR, PHARMACEUTICAL PRODUCT, OPHTHALMIC AGENT, EYE DROPS, COMPOSITION, AND METHOD FOR PRODUCING COMPOUND | UNIV KYOTO (JP) | 2026-03-12 | — | — | US | disclosed |
| US-12415949-B2 | Compound, organic electroluminescent device, and display device | SK INC. (KR) | 2025-09-16 | — | — | US | disclosed |
| US-20250248990-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | NEURODON CORPORATION | 2025-08-07 | — | — | US | disclosed |
| EP-4582430-A1 | COMPOUND, ENDOPLASMIC RETICULUM STRESS INHIBITOR, PHARMACEUTICAL PRODUCT, OPHTHALMIC AGENT, EYE DROPS, COMPOSITION, AND METHOD FOR PRODUCING COMPOUND | Kyoto University (JP) | 2025-07-09 | — | — | EP | disclosed |
| US-12144806-B2 | Quinolines that modulate SERCA and their use for treating disease | NEURODON CORPORATION (US) | 2024-11-19 | — | — | US | disclosed |
| US-20240277694-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | NEURODON CORPORATION | 2024-08-22 | — | — | US | disclosed |
| US-11992487-B2 | Quinolines that modulate SERCA and their use for treating disease | NEURODON CORPORATION (US) | 2024-05-28 | — | — | US | disclosed |
| WO-2024048697-A1 | COMPOUND, ENDOPLASMIC RETICULUM STRESS INHIBITOR, PHARMACEUTICAL PRODUCT, OPHTHALMIC AGENT, EYE DROPS, COMPOSITION, AND METHOD FOR PRODUCING COMPOUND | 国立大学法人京都大学 | 2024-03-07 | — | — | WO | disclosed |
| US-5426191-A | Treating substituted cinnamic acids with 4-N,N*-disubstituted aminopyridines, then with thionyl chloride | WARNER-LAMBERT COMPANY (US) | 1995-06-20 | — | — | US | disclosed |
| WO-1995015323-A1 | IMPROVED PROCESS FOR THE SYNTHESIS OF 3-CHLOROBENZO[b]THIOPHENE-2-CARBONYL CHLORIDES | WARNER-LAMBERT COMPANY (US) | 1995-06-08 | — | — | WO | disclosed |
| WO-1995015323-A1 | IMPROVED PROCESS FOR THE SYNTHESIS OF 3-CHLOROBENZO[b]THIOPHENE-2-CARBONYL CHLORIDES | WARNER-LAMBERT COMPANY (US) | 1995-06-08 | — | — | WO | disclosed |
| EP-0640592-A1 | N-acylated tricyclic azaheterorings useful as vasopressin antagonists | AMERICAN CYANAMID COMPANY (US) | 1995-03-01 | — | — | EP | disclosed |
| EP-0636625-A2 | Tricyclic diazepine vasopressin antagonists and oxytocin antagonists | AMERICAN CYANAMID COMPANY (US) | 1995-02-01 | — | — | EP | disclosed |
| US-5350748-A | 3-thio or amino substituted-benzo[b]thiophene-2-carboxamides and 3-oxygen, thio, or amino substituted-benzofuran-2-carboxamides as inhibitors of cell adhesion | WARNER-LAMBERT COMPANY (US) | 1994-09-27 | — | — | US | disclosed |
| US-4489089-A | INHIBITION OF THE ENZYME THROMBOXANE SYNTHETASE | AMERICAN CYANAMID COMPANY (US) | 1984-12-18 | — | — | US | disclosed |
| EP-0127727-A2 | Substituted N-(omega-(1H-imidazol-1-yl)alkyl)) amides | AMERICAN CYANAMID COMPANY (US) | 1984-12-12 | — | — | EP | disclosed |
| US-4259336-A | ANALGESIC, ANTIPYRETIC, ANTITHROMBOTIC, ANTIPHLOGISTIC | BOEHRINGER INGELHEIM GMBH (DE) | 1981-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070921-A1 | COMPOUND, ENDOPLASMIC RETICULUM STRESS INHIBITOR, PHARMACEUTICAL PRODUCT, OPHTHALMIC AGENT, EYE DROPS, COMPOSITION, AND METHOD FOR PRODUCING COMPOUND | XBP1, HSPA5, DNAJC10 | MCL1 3585/4885HDAC1 2618/4885HDAC8 2625/4885 |
| US-11992487-B2 | Quinolines that modulate SERCA and their use for treating disease | ATP2A1, ATP2A3, ATP2A2 | MCL1 4536/4885HDAC1 2929/4885HDAC8 3019/4885 |
| US-12415949-B2 | Compound, organic electroluminescent device, and display device | L1CAM, EML4, OCIAD2 | MCL1 4150/4885HDAC1 4349/4885HDAC8 4533/4885 |
| US-12144806-B2 | Quinolines that modulate SERCA and their use for treating disease | ATP2A1, ATP2A3, ATP2A2 | MCL1 4536/4885HDAC1 2929/4885HDAC8 3019/4885 |
| US-20250248990-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | ATP2A1, ATP2A3, ATP2A2 | MCL1 4536/4885HDAC1 2929/4885HDAC8 3019/4885 |
| US-20240277694-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | ATP2A1, ATP2A3, ATP2A2 | MCL1 4536/4885HDAC1 2929/4885HDAC8 3019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.